Sandu Pharmaceuticals Limited has submitted a regulatory disclosure to BSE Limited regarding a change in the name of one of its directors. The company intimates that Dr. Neeti Madan Kapre (DIN: 06801264), who serves as Non Executive Independent Director of the Company, has changed her name to Dr. Neeti Gupta consequent upon her marriage.
The change in name has been duly supported by relevant documentary evidence and has been taken on record by the Company. The disclosure explicitly confirms that there is no change in the director's designation, directorship status, or DIN (Director Identification Number). The intimation is solely regarding the change in her name.
The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The annexure provides additional details as required under the regulation, specifying that the change affects managerial personnel and the reason for change is specifically "Change of Name from Dr Neeti Madan Kapre (DIN:06801264) to Dr Neeti Gupta."
No other changes to the director's profile, appointment date, term, relationships, or other particulars are reported, with relevant fields marked as "NA" (Not Applicable).
The document is signed by Pratika Mhambray, Company Secretary and Compliance Officer (ACS 36512), and includes digital signature verification dated 2026.10.09.
Financial Impact
No financial impact disclosed. The change is purely administrative regarding director name records.